CLINICAL TRIALS PROFILE FOR MIRAPEX ER

All Clinical Trials for MIRAPEX ER

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00025792 ↗	Clinical Trial of Pramipexole in Bipolar Depression	Completed	National Institute of Mental Health (NIMH)	Phase 2	2001-10-01	The purpose of this study is to examine the safety and effectiveness of the drug pramipexole given in combination with lithium or divalproex for the short-term treatment of acute depression in patients with bipolar disorder. Bipolar disorder is a severe, chronic, and often life-threatening illness. Treatments for acute unipolar depression have been extensively researched. However, despite the availability of a wide range of antidepressant drugs, a significant proportion of depressed patients fail to respond to first-line antidepressant treatment. Novel and improved therapeutics for bipolar depression are needed. This study will evaluate the antidepressant properties of pramipexole. This study will be conducted in three phases. Phase 1 is a 14-day washout period in which participants will be tapered off all their psychiatric medicines except divalproex or lithium. Participants will also be asked to adhere to a low caffeine and low monoamine diet. During Phase 2, participants will be randomly assigned to receive either pramipexole or placebo (an inactive pill) for 6 weeks. Participants who respond to treatment will be given either open-label pramipexole or another clinical treatment. Participants will be screened with a medical history, physical examination, electrocardiogram (EKG), blood and urine tests, and a psychiatric evaluation. Women of childbearing potential will have a pregnancy test. Participants will have a physical exam and EKG at study entry and study completion. Blood will be drawn at various times throughout the study. Pulse and blood pressure measurements will be taken daily. Weekly interviews will be conducted. Participants and a control group of healthy volunteers will undergo positron emission tomography (PET) and magnetic resonance imaging (MRI) scans of the brain.
NCT00040209 ↗	JP-1730 to Treat Parkinson's Disease	Completed	National Institute of Neurological Disorders and Stroke (NINDS)	Phase 2	2002-06-01	This study will evaluate the effects of an experimental drug called JP-1730 on Parkinson's disease symptoms and on dyskinesias (involuntary movements) that develop as a result of long-term treatment with levodopa. JP-1730 affects chemical messengers believed to affect Parkinson's disease symptoms. Patients between 30 and 80 years of age with relatively advanced Parkinson's disease may be eligible for this 3-phase study. - Phase 1 - Baseline evaluation Participants will be evaluated with a medical history, physical examination, detailed neurologic evaluation, routine blood tests, urinalysis and an electrocardiogram. They will also have a 24-hour holter monitor (heart monitoring) and cardiology consultation. A chest X-ray and MRI or CT scan of the brain will be done if needed. Patients will, if possible, stop taking all antiparkinsonian medications except levodopa (Sinemet) for one month before the study begins and throughout its duration. (If necessary, patients may use short-acting dopamine agonists, such as Mirapex and Requip.) - Phase 2 - Dose Finding Phase For 2 to 3 days, patients will be admitted to the NIH Clinical Center for a levodopa (a dopamine agonist) dose-finding procedure. For this procedure, patients stop taking Sinemet and instead have levodopa, and subsequently apomorphine, infused through a vein. During the infusions, the drug dose is increased slowly until either 1) parkinsonian symptoms improve, 2) unacceptable side effects occur, or 3) the maximum study dose is reached. Symptoms are monitored frequently to find the optimal dose. (Patients who have had dosing infusions in the last 3 months will not have to undergo this phase of the study.) - Phase 3 - Active Study Phase Within 3 months of the dose-finding phase, treatment will begin. Patients will receive seven doses of JD-1730 or placebo (an inactive substance) via puffs from an oral spray together with levodopa infusions over a 3-week period. The doses are given on days 1, 2, and 3 of the first week and then approximately twice a week for the next 2 weeks. For these doses, patients are hospitalized 4 days the first week and 2 days each for the next 2 weeks. All participants will receive placebo at some time during the study, and a few patients, selected at random, will receive only placebo the entire 3 weeks. The procedure for the infusions is the same as that for the dose-finding phase, with frequent evaluation of symptoms. Also, small blood samples are drawn up to three times each study day. At the end of the third week, patients will be discharged from the hospital. Their anti-parkinsonian medications may be readjusted, as needed. Patients will be contacted 2 weeks after the end of the study for a check on side effects and, if necessary, will be scheduled for a follow-up evaluation at the clinic. In addition to the above procedures, patients will be asked to have an optional lumbar a puncture (spinal tap) on the first and last days of the study to measure various brain chemicals and drug levels that cannot be measured in blood and urine. For this procedure, a local anesthetic is given and a needle is inserted in the space between the bones (vertebrae) in the lower back. About 2 tablespoons of fluid is collected through the needle.
NCT00076674 ↗	Levetiracetam Treatment of L-dopa Induced Dyskinesias	Completed	National Institute of Neurological Disorders and Stroke (NINDS)	Phase 2	2004-01-01	This study will evaluate the effects of levetiracetam (Keppra (Trademark) on Parkinson's disease symptoms and on dyskinesias (involuntary movements) that develop as a result of long-term treatment with levodopa. Levetiracetam blocks certain protein receptors on brain cells and thus can change the spread of brain signals believed to be affected in patients with Parkinson's disease. Patients between 30 and 80 years of age with relatively advanced Parkinson's disease and dyskinesias due to levodopa therapy may be eligible for this 6-week study. Screening and baseline evaluation - Participants are evaluated with a medical history, physical examination and neurologic evaluation, blood tests, urinalysis, electrocardiogram (EKG), 24-hour holter monitor (heart monitoring), and cardiology consultation. A chest x-ray and MRI or CT scan of the brain are done if needed. If possible, patients stop taking all antiparkinsonian medications except levodopa (Sinemet) for one month (2 months if taking Selegiline) before the study begins and throughout its duration. (If necessary, patients may use short-acting agents, such as Mirapex, Requip or Amantadine.) Dose-finding phase - Patients are admitted to the NIH Clinical Center for 2 to 3 days for a levodopa "dose-finding" procedure. For this test, patients stop taking Sinemet and instead have levodopa infused through a vein. During the infusions, the drug dose is increased slowly until parkinsonian symptoms improve or unacceptable side effects occur or the maximum study dose is reached. Symptoms are monitored frequently. (Patients who have had dosing infusions in the last 3 months do not have to undergo this phase of the study.) Active study phase - Patients are randomly assigned to take levetiracetam or placebo ("sugar pill") twice a day for 6 weeks. At the end of weeks 1, 2 4, and 5, patients come to the clinic for blood tests, an EKG, and a review of adverse side effects. At the end of weeks 3 and 6, patients are hospitalized to study the response to treatment. They again stop taking Sinemet and selegiline and their ability to perform motor tasks is evaluated. They are then placed on an L-dopa infusion for 10 hours. Placebo may be infused at various times instead of L-dopa. Motor symptoms are evaluated several times during the infusion. Blood is drawn once during the infusion for research studies. Lumbar puncture - Patients undergo a lumbar puncture (spinal tap) at the end of weeks 1 and 4 to measure certain brain chemicals and drug levels. For this test, a local anesthetic is given and a needle is inserted in the space between the vertebrae in the lower back. About 2 tablespoons of fluid is collected through the needle. Magnetic resonance imaging (MRI) - Patients with changing disease activity may undergo MRIs at baseline, at the end of week 1 and at the end of the study to show changes in the brain. The patient lies in a narrow cylinder (the scanner) that uses radio waves and a magnetic field to produce images of the brain, which show structural and chemical changes. Follow-up - 2 weeks after the study ends, patients are contacted by phone for a review of side effects or they return to the clinic for an evaluation.

Clinical Trial Conditions for MIRAPEX ER

Condition Name

Condition Name for MIRAPEX ER
Intervention	Trials
Parkinson Disease	9
Restless Legs Syndrome	6
Parkinson's Disease	5

Condition MeSH

Condition MeSH for MIRAPEX ER
Intervention	Trials
Parkinson Disease	15
Restless Legs Syndrome	7
Psychomotor Agitation	7

Clinical Trial Locations for MIRAPEX ER

Trials by Country

Trials by Country for MIRAPEX ER
Location	Trials
United States	173
Canada	9
Spain	4
Finland	3
Italy	3

Trials by US State

Trials by US State for MIRAPEX ER
Location	Trials
Maryland	11
New York	10
Massachusetts	10
California	9
Texas	8

Clinical Trial Progress for MIRAPEX ER

Clinical Trial Phase

Clinical Trial Phase for MIRAPEX ER
Clinical Trial Phase	Trials
Phase 4	9
Phase 3	7
Phase 2/Phase 3	1

Clinical Trial Status

Clinical Trial Status for MIRAPEX ER
Clinical Trial Phase	Trials
Completed	25
Unknown status	4
Not yet recruiting	1

Clinical Trial Sponsors for MIRAPEX ER

Sponsor Name

Sponsor Name for MIRAPEX ER
Sponsor	Trials
Boehringer Ingelheim	7
National Institute of Neurological Disorders and Stroke (NINDS)	4
GlaxoSmithKline	3

Sponsor Type

Sponsor Type for MIRAPEX ER
Sponsor	Trials
Other	22
Industry	20
NIH	8

MIRAPEX ER: Clinical Trial Landscape, Market Dynamics, and Future Projections

Last updated: February 19, 2026

Mirapex ER (pramipexole extended-release) is a dopamine agonist approved for the treatment of Parkinson's disease (PD) and restless legs syndrome (RLS). The drug's patent landscape and ongoing clinical developments influence its market position and future growth. This analysis examines key clinical trial data, market performance, and projected trends for Mirapex ER.

What is the Current Status of Mirapex ER Clinical Trials?

As of the latest available data, Mirapex ER has undergone significant clinical evaluation, primarily focused on its efficacy and safety in treating Parkinson's disease and restless legs syndrome. The drug's development pipeline is largely mature, with post-marketing studies and real-world evidence gathering continuing.

• Parkinson's Disease (PD):

  • Initial Approvals: Mirapex ER received FDA approval for PD in January 2009. The initial trials established its efficacy in managing motor symptoms.
  • Key Trials: Pivotal trials, such as the one published in The Lancet Neurology (2006), demonstrated pramipexole extended-release's superiority over placebo in improving motor scores in PD patients. Studies also compared its efficacy against immediate-release formulations and other dopaminergic agents.
  • Ongoing Investigations: Post-marketing surveillance and observational studies continue to monitor long-term safety and effectiveness in broader patient populations. These studies aim to gather real-world data on patient adherence, tolerability, and potential off-label uses or specific subgroup benefits.

• Restless Legs Syndrome (RLS):

  • FDA Approval: Mirapex ER received FDA approval for RLS in June 2010.
  • Efficacy Studies: Clinical trials for RLS demonstrated a significant reduction in the severity of symptoms, as measured by the Restless Legs Syndrome Rating Scale (RLS RS). Studies showed improvement in sleep quality and daytime functioning.
  • Dose Optimization: Research has focused on identifying optimal dosing strategies for RLS patients, balancing symptom control with potential side effects.

• Combination Therapies and Novel Applications: While not the primary focus for Mirapex ER, research into dopaminergic agents, in general, explores their potential in conjunction with other PD therapies, such as levodopa, to manage fluctuating motor symptoms. No major clinical trials are currently active for Mirapex ER in novel therapeutic areas beyond its approved indications.

How is Mirapex ER Performing in the Market?

Mirapex ER, marketed by Boehringer Ingelheim, has established a significant presence in the market for Parkinson's disease and restless legs syndrome. Its performance is influenced by patent expiry, generic competition, and the evolving treatment landscape.

• Market Size and Share: The market for Parkinson's disease therapeutics is substantial and growing, driven by an aging global population. Mirapex ER has captured a notable share of this market due to its established efficacy and extended-release formulation, offering convenience over immediate-release versions.

  • In 2022, the global Parkinson's disease drug market was valued at approximately $4.7 billion and is projected to reach over $7.7 billion by 2030, growing at a CAGR of 6.4% (Source: Fortune Business Insights). Mirapex ER contributes to this valuation.
  • The RLS market, while smaller, also represents a significant segment where Mirapex ER is a key player.

• Sales Performance: While specific current sales figures for Mirapex ER are not publicly disclosed by Boehringer Ingelheim as a standalone product, its performance contributes to the broader dopamine agonist category.

  • Generic Competition: A critical factor impacting sales is the expiry of key patents. The composition of matter patent for pramipexole expired, leading to the introduction of generic versions of both immediate-release and extended-release pramipexole. This has intensified competition and placed downward pressure on pricing.
  • Brand vs. Generic: Branded Mirapex ER often maintains a market share due to physician familiarity, patient loyalty, and perceived quality. However, generic penetration is significant, particularly in the United States and European markets. Generic pramipexole extended-release formulations are available from multiple manufacturers.

• Competitive Landscape: Mirapex ER competes with a range of therapeutic agents for PD and RLS.

  • Parkinson's Disease:
    • Other Dopamine Agonists: Rotigotine (Neupro), Ropinirole (Requip, Requip XL).
    • Levodopa/Carbidopa: Still the gold standard for motor symptom management.
    • MAO-B Inhibitors: Selegiline, Rasagiline, Safinamide.
    • COMT Inhibitors: Entacapone, Tolcapone.
  • Restless Legs Syndrome:
    • Other Dopamine Agonists: Ropinirole, Rotigotine.
    • Alpha-2 Delta Ligands: Gabapentin, Pregabalin.

• Pricing and Reimbursement: Pricing strategies for Mirapex ER are influenced by its branded status, the presence of generics, and payer policies. Reimbursement rates vary by region and insurance provider. The availability of lower-cost generic alternatives impacts the pricing power of the branded product.

What are the Future Projections for Mirapex ER?

The future trajectory of Mirapex ER will be shaped by several interconnected factors including patent expiration impacts, the introduction of novel therapies, and evolving treatment paradigms for Parkinson's disease and restless legs syndrome.

• Impact of Genericization: The continued availability and adoption of generic pramipexole extended-release will remain the most significant market dynamic. This trend is expected to accelerate market share erosion for the branded Mirapex ER, forcing a focus on market segments where brand loyalty or physician preference can still command a premium.

  • Generic pramipexole ER formulations are widely available in major markets. For example, in the US, Teva Pharmaceuticals, Mylan (now Viatris), and others offer generic pramipexole ER tablets.
  • Price erosion due to generic competition is a well-documented phenomenon in the pharmaceutical industry. Branded drug sales typically decline by 70-90% after the introduction of generics.

• Pipeline and Innovation: The development of novel therapies for PD and RLS could impact Mirapex ER's market position.

  • Disease-Modifying Therapies: The long-term outlook for PD treatment centers on therapies that could slow or halt disease progression, rather than solely managing symptoms. While such therapies are still in early to mid-stage development, their eventual introduction will fundamentally alter the treatment landscape.
  • New Mechanisms of Action: Research is exploring new drug targets beyond dopamine modulation, potentially offering alternative or adjunctive treatments for both PD and RLS.

• Treatment Guidelines and Physician Preferences: Evolving clinical practice guidelines and physician preferences will influence prescribing patterns. While pramipexole ER remains a recommended option for certain patient profiles, newer agents or combination therapies may gain favor.

  • The European Federation of Neurological Societies (EFNS) and the American Academy of Neurology (AAN) provide guidelines that are regularly updated, reflecting new research and clinical evidence. These guidelines are instrumental in shaping physician choice.

• Geographic Market Dynamics: The penetration of generics and the market growth for PD and RLS treatments vary significantly by region.

  • Mature Markets (North America, Europe): These markets are characterized by established healthcare systems and rapid generic uptake. Growth is driven by aging populations, but the overall market value for branded Mirapex ER may stagnate or decline.
  • Emerging Markets (Asia-Pacific, Latin America): These regions may offer growth opportunities due to increasing healthcare access and diagnosis rates. However, pricing pressures and the availability of generics will still be significant factors.

• Extended-Release Formulation Advantage: The extended-release formulation of pramipexole provides a consistent plasma concentration, reducing fluctuations in symptom control and potentially minimizing certain side effects associated with immediate-release dopamine agonists. This characteristic will likely sustain its utility for a segment of patients, even in the presence of generics.

  • The bioavailability of pramipexole extended-release is approximately 87% compared to oral solution.
  • The extended-release formulation allows for once-daily dosing, improving patient compliance compared to multiple daily doses of immediate-release formulations.

• Market Size and Growth Outlook: Despite the pressures from genericization, the overall market for PD and RLS treatments is projected to grow. Mirapex ER, or its generic equivalent, will continue to be a relevant therapeutic option.

  • The global RLS market is projected to grow, with estimates varying but generally indicating a compound annual growth rate in the low to mid-single digits.

Table 1: Mirapex ER Key Market Factors

Factor	Description	Impact on Mirapex ER
Patent Expiration	Composition of matter and other key patents have expired.	Significant increase in generic competition, leading to price erosion and market share decline for branded Mirapex ER.
Generic Availability	Multiple manufacturers offer generic pramipexole extended-release formulations.	Intensifies price competition, driving down overall revenue for the pramipexole ER market.
Dopamine Agonist Class	Mirapex ER belongs to this established class of PD and RLS treatments.	Benefits from the established efficacy and understanding of the mechanism of action for dopamine agonists.
Extended-Release	Delivers a consistent dose over 24 hours.	Offers convenience (once-daily dosing) and potentially improved tolerability, providing a competitive advantage over IR.
Therapeutic Area Growth	Aging populations drive demand for PD and RLS treatments.	Provides an underlying growth driver for the pramipexole ER market, even with generic competition.
Novel Therapies	Emerging treatments for PD and RLS with different mechanisms of action.	Potential to reduce the reliance on dopamine agonists, impacting long-term market share for Mirapex ER and its generics.

Key Takeaways

Mirapex ER (pramipexole extended-release) holds a solidified position in the Parkinson's disease and restless legs syndrome markets. Its efficacy and the convenience of its extended-release formulation have driven significant market penetration. However, the expiration of key patents has led to robust generic competition, exerting considerable downward pressure on pricing and branded market share. While the overall therapeutic area is projected for continued growth, driven by demographic trends, the market dynamics for Mirapex ER are now primarily defined by its generic counterparts. Future market performance will depend on the sustained utility of the pramipexole mechanism of action, evolving treatment guidelines, and the eventual introduction of disease-modifying therapies or alternative treatment modalities.

Frequently Asked Questions

1. What is the primary mechanism of action for Mirapex ER? Mirapex ER is a dopamine agonist that stimulates dopamine receptors in the brain, mimicking the effects of naturally occurring dopamine. This helps to alleviate motor symptoms in Parkinson's disease and the sensory symptoms associated with restless legs syndrome.

2. How does the extended-release formulation of Mirapex ER differ from its immediate-release counterpart? The extended-release formulation is designed to release the active ingredient, pramipexole, gradually over a 24-hour period, allowing for once-daily dosing. This contrasts with immediate-release formulations, which require multiple daily doses and can lead to more pronounced fluctuations in drug levels and potentially more intermittent symptom control.

3. What is the impact of generic pramipexole ER on the market for branded Mirapex ER? The introduction of generic pramipexole extended-release has led to significant price competition and a substantial decline in the market share and revenue for branded Mirapex ER. Healthcare providers and payers often favor the lower-cost generic alternatives when clinically appropriate.

4. Are there any new clinical trials investigating Mirapex ER for conditions other than Parkinson's disease and restless legs syndrome? As of current public data, there are no major clinical trials actively investigating Mirapex ER for indications beyond Parkinson's disease and restless legs syndrome. Its development pipeline is focused on post-marketing surveillance and real-world evidence gathering for its approved uses.

5. What are the key competing drug classes for Mirapex ER? For Parkinson's disease, Mirapex ER competes with other dopamine agonists (e.g., ropinirole, rotigotine), levodopa/carbidopa, MAO-B inhibitors, and COMT inhibitors. For restless legs syndrome, it competes with other dopamine agonists and alpha-2 delta ligands such as gabapentin and pregabalin.

Citations

[1] Fortune Business Insights. (2023). Global Parkinson's Disease Drugs Market Size, Share & COVID-19 Impact Analysis, By Drug Type (Dopamine Agonists, Levodopa, MAO-B Inhibitors, Others), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), and Regional Forecasts, 2023-2030. Retrieved from https://www.fortunebusinessinsights.com/parkinsons-disease-drugs-market-104275 [2] Excerpts from publicly available prescribing information for Mirapex ER and generic pramipexole extended-release products were reviewed for pharmacokinetic data and formulation characteristics. [3] Clinical trial databases (e.g., ClinicalTrials.gov) were searched for ongoing and completed trials related to pramipexole extended-release. [4] Pharmaceutical industry market analysis reports and company financial statements (where available for specific product categories) were consulted for market trend data and competitive landscape information.